Role of Sphingolipids in Pulmonary Edema (09-045)
This study is currently recruiting participants.
Verified December 2012 by RWTH Aachen University
Sponsor:
RWTH Aachen University
Information provided by (Responsible Party):
RWTH Aachen University
ClinicalTrials.gov Identifier:
NCT01162161
First received: July 13, 2010
Last updated: December 13, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this mono-center prospective study, the impact of changes in the sphingolipid metabolism in patients with pulmonary edema will be investigated.
| Condition |
|---|
|
Pulmonary Edema |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Crossover Time Perspective: Prospective |
| Official Title: | Role of Sphingolipids in Pulmonary Edema |
Resource links provided by NLM:
Further study details as provided by RWTH Aachen University:
| Estimated Enrollment: | 70 |
| Study Start Date: | July 2010 |
| Estimated Study Completion Date: | May 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
hydrostatic pulmonary edema
patients with a pulmonary edema caused by chronic heart failure
|
|
toxic pulmonary edema
patients with a pulmonary edema preceded by pneumonia
|
|
control group
not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
|
Detailed Description:
There will be three groups of patients:
- hydrostatic pulmonary edema
- toxic pulmonary edema
- not ventilated patients without any pulmonary edema
Samples of a routine bronchoalveolar lavage and EDTA-blood will be analysed in respect of sphingolipids, ceramide, sphingomyelin-phosphodiesterase and several cytokines.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
3 groups
first group: patients with a lung oedema because of a pneumonia (about 30 patients)
second group: patients with a lung oedema because of cardiac insufficiency (about 25 patients)
third group: patients without any lung oedema (about 15 patients)
Criteria
Inclusion Criteria:
- above the age of 18
Exclusion Criteria:
- taking steroids
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01162161
Contacts
| Contact: Stefan Krueger, PD Dr. med. | 0049-241-8085152 | stkrueger@ukaachen.de |
Locations
| Germany | |
| Medical Clinic I, University Hospital Aachen | Recruiting |
| Aachen, Nordrhein-Westfalen, Germany, 52074 | |
| Contact: Stefan Krüger, PD Dr. med. stkrueger@ukaachen.de | |
Sponsors and Collaborators
RWTH Aachen University
Investigators
| Principal Investigator: | Stefan Krüger, MD, PhD | RWTH Aachen University |
More Information
No publications provided
| Responsible Party: | RWTH Aachen University |
| ClinicalTrials.gov Identifier: | NCT01162161 History of Changes |
| Other Study ID Numbers: | Sphingo-AC |
| Study First Received: | July 13, 2010 |
| Last Updated: | December 13, 2012 |
| Health Authority: | Germany: Ethics Committee |
Keywords provided by RWTH Aachen University:
|
sphingolipid ceramide sphingomyelinase |
Additional relevant MeSH terms:
|
Edema Pulmonary Edema Signs and Symptoms Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on June 17, 2013